Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
753.93
+0.38 (+0.05%)
Streaming Delayed Price
Updated: 10:21 AM EST, Jan 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
↗
September 08, 2025
Regeneron's Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the way for future development.
Via
Benzinga
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials
↗
September 08, 2025
Via
Stocktwits
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
September 08, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Beaten-Down Stocks to Buy on the Dip
↗
September 07, 2025
The market may be overlooking these companies' long-term potential.
Via
The Motley Fool
Topics
Government
World Trade
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
September 04, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon
↗
August 26, 2025
Via
Stocktwits
Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions
↗
August 20, 2025
Via
Stocktwits
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
↗
September 04, 2025
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.
Via
Benzinga
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
↗
September 04, 2025
Can anything beat out Dupixent's "compelling bar" for effectiveness?
Via
Investor's Business Daily
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
September 03, 2025
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Cisco, ServiceNow, Truist Financial And A Health Care Stock On CNBC's 'Final Trades'
↗
September 02, 2025
Cisco reported fourth-quarter revenue of $14.67 billion, and there was a bout of profit taking, Cerity Partners' Jim Lebenthal says.
Via
Benzinga
REGENERON PHARMACEUTICALS (NASDAQ:REGN): A Prime Value Investing Candidate with Strong Fundamentals
↗
August 29, 2025
Discover REGN, a top value investing stock. It boasts strong fundamentals, low P/E ratios, high profitability, and solid financial health, trading below its intrinsic worth.
Via
Chartmill
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
August 27, 2025
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
↗
August 27, 2025
Via
Benzinga
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
↗
August 26, 2025
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026.
Via
Benzinga
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
August 26, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Top S&P500 movers in Monday's session
↗
August 25, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Via
Chartmill
FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles
↗
August 25, 2025
Novo Nordisk's acquired facility faces scrutiny over recurring contamination, incomplete investigations, and ineffective corrective actions.
Via
Benzinga
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
↗
August 24, 2025
These companies aren't performing as badly as their stock-market performances this year suggest.
Via
The Motley Fool
What's going on in today's session: S&P500 movers
↗
August 21, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.
Via
Chartmill
Exploring the top movers within the S&P500 index during today's session.
↗
August 20, 2025
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.
Via
Chartmill
What's going on in today's session: S&P500 movers
↗
August 20, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
Via
Chartmill
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
August 20, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 of Wall Street’s Favorite Stocks with Open Questions
August 19, 2025
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...
Via
StockStory
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
August 17, 2025
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers.
Via
StockStory
Topics
Artificial Intelligence
These S&P500 stocks are moving in today's session
↗
August 14, 2025
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
Via
Chartmill
REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
August 12, 2025
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was...
Via
StockStory
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
August 12, 2025
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...
Via
StockStory
Topics
Bonds
Economy
Lawsuit
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
↗
August 11, 2025
Truist, however, kept a ‘Buy’ rating on the shares.
Via
Stocktwits
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings
↗
August 11, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
